Kevin Hern | VP, IR |
Dave Ricks | Chairman and CEO |
Josh Smiley | CFO |
Dr. Dan Skovronsky | Chief Scientific Officer |
Anne White | President, Lilly Oncology |
Patrik Jonsson | President, Lilly Bio-Medicines |
Mike Mason | President, Lilly Diabetes |
Terence Flynn | Goldman Sachs |
Chris Schott | JPMorgan |
Andrew Baum | Citi |
David Risinger | Morgan Stanley |
Seamus Fernandez | Guggenheim |
Steve Scala | Cowen |
Navin Jacob | UBS |
Umer Raffat | Evercore |
Geoff Meacham | Bank of America |
Louise Chen | Cantor |
Vamil Divan | Mizuho Securities |
Tim Anderson | Wolfe Research |
Carter Gould | Barclays |
Ladies and gentlemen, thank you for standing by. Welcome to the Lilly Q1 Earnings Conference Call.
At this time, all participants are in a listen-only mode. [Operator Instructions] As a reminder, your conference call today is being recorded.
I’ll now turn the conference call over to your host, Vice President of Investor Relations, Kevin Hern.